Q-omics provides the consensus-scored CRYGN profile across patient tissues and cancer cell-line models. CRYGN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CRYGN is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CRYGN RNA expression shows 13,184 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, and TGCT as cancer lineages where CRYGN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYGN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYGN survival associations across molecular data types. CRYGN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYGN RNA expression–survival associations across cancer types. High CRYGN expression shows unfavorable associations in KIRC, ACC, LUSC, STAD and GBM, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CRYGN RNA expression.
This table summarizes CRYGN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CRYGN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYGN shows lower tumor expression in KICH, BRCA and PRAD and higher tumor expression in LUAD, HNSC and LUSC. The LUAD box plot shows higher CRYGN RNA expression in tumor versus normal tissue (log2 FC = +0.634, t-test p < 0.001).
This table shows molecular features associated with CRYGN in patient tissues and cancer cell lines. In patient samples, CRYGN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYGN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
